The downregulation of LATS1 and LATS2 has been observed in astrocytoma, breast cancer, colon cancer, gliomas and non-small cell lung cancer, and is directly associated with a poor prognosis [30–32]. This evidence concerns the gene LATS2 and central nervous system cancer.